Numerous studies claim that in moderation, dark chocolate is good for our health. Now, a new study published in the Journal of the American Heart Association adds to the evidence, suggesting that it may help increase walking distance for people with peripheral artery disease.
A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target.
Los hombres mayores que fuman o que han fumado cien o más cigarrillos deben recibir pruebas de detección para un aneurisma aórtico abdominal, recomienda un panel de expertos en salud de Estados Unidos.
In a multicentre randomised trial, a silver alginate dressing failed to reduce wound complications in patients undergoing open lower limb procedures. The results were presented at the Society for Vascular Surgery Annual Meeting (5–7 June, Boston, USA).
Bristol-Myers Squibb Company and Pfizer have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Eliquis (apixaban) be granted marketing authorisation for the treatment of deep vein thrombosis and pulmonary embolism, and the prevention of recurrent deep vein thrombosis and pulmonary embolism, in adults. The CHMP’s positive opinion will now be reviewed by the European Commission. The decision on whether to approve apixaban for this indication will be made by the European Commission and will be applicable to all European Union member states plus Iceland and Norway.
Lombard Medical exhibited its Aorfix endovascular stent graft system at the 18th international experts’ symposium, Critical Issues in Aortic Endografting, in Malmö, Sweden on 27–28 June 2014.
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients treated with endovascular aneurysm repair (EVAR) in the study, with an incidence of 31%. Wei Zhou, who presented the results of the analysis, said that 53% of the endoleaks seen in the trial resolved spontaneously.
Results from a feasibility study conducted in Italy indicate that ultrasound-enhanced paclitaxel delivery inhibits arterial smooth muscle proliferation after balloon angioplasty in peripheral arterial disease. Costantino Del Giudice, Department of Radiology, University Hospital Tor Vergata, Rome, Italy, spoke about the study at the EuroPCR congress (19–23 May, Paris, France).
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients treated with endovascular aneurysm repair (EVAR) in the study, with an incidence of 31%. Wei Zhou, who presented the results of the analysis, said that 53% of the endoleaks seen in the trial resolved spontaneously.
Biotronik has announced the publication of clinical results from the PEACE I All-Comers registry in The Journal of Endovascular Therapy. Along with earlier results from the 4EVER trial, PEACE I confirms the safety and efficacy of the Pulsar-18 stent with positive patency results, further establishing the benefits of 4 French (4F) intervention in treating even more advanced cases of femoropopliteal disease.
A new issue of the Journal of Endovascular Therapy features an article comparing drug-coated balloons and drug-eluding stents for their performance in femoropopliteal lesions measuring 10 centimeters or longer. While the researches concluded that there was no significant difference between the two treatments, the author of a commentary article predicts that both of these treatments may become first-line therapy for femoropopliteal artery disease.
June 15, 2014—Medtronic, Inc. and Covidien announced that they have entered into a definitive agreement under which Medtronic has agreed to acquire Covidien. The businesses of Medtronic and Covidien will be combined under a new entity to be called Medtronic plc, which will have its principal executive offices in Ireland and its operational headquarters in Minneapolis, Minnesota. Covidien’s headquarters are currently in Ireland, where both companies have a longstanding presence. Medtronic’s Chairman and Chief Executive Officer Omar Ishrak will lead Medtronic plc.
June 13, 2014—Biotronik announced the publication of clinical results from the PEACE I All-Comers Registry by Michael Lichtenberg, MD, et al in The Journal of Endovascular Therapy (2014;21:373–380). The company stated that along with earlier results from the 4EVER trial, PEACE I confirms the safety and efficacy of the company’s 4-F Pulsar-18 stent for treating advanced cases of femoropopliteal disease. The 12-month PEACE data and the 24-month 4EVER data were presented in September at CIRSE 2013, the annual congress of the Cardiovascular and Interventional Radiological Society in Barcelona, Spain.
June 12, 2014—Bard Peripheral Vascular announced that a Circulatory System Devices Panel of the Medical Devices Advisory Committee of the US Food and Drug Administration (FDA) provided a unanimous favorable recommendation to the FDA for approval of the Lutonix drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) catheter for the treatment of peripheral arterial disease (PAD) in the United States.
June 12, 2014—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the publication of a new appropriate use expert consensus document to provide guidance for femoropopliteal arterial interventions. The SCAI noted that blockage affecting arteries above the knee is the most common form of peripheral artery disease (PAD). The document was published by Andrew J. Klein MD, et al and is available online in Catheterization and Cardiovascular Interventions.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos